Radiation Oncology Journal

  • 제28권4호
  • /
  • Pages.193-204
  • /
  • 2010
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

이차원방사선치료를 시행한 코인두암 환자의 장기 추적 결과 및 예후인자 분석

Long-Term Results of 2-Dimensional Radiation Therapy in Patients with Nasopharyngeal Cancer

  • 이남권 (고려대학교 의과대학 방사선종양학교실) ;
  • 박영제 (고려대학교 의과대학 방사선종양학교실) ;
  • 양대식 (고려대학교 의과대학 방사선종양학교실) ;
  • 윤원섭 (고려대학교 의과대학 방사선종양학교실) ;
  • 이석 (고려대학교 의과대학 방사선종양학교실) ;
  • 김철용 (고려대학교 의과대학 방사선종양학교실)
  • Lee, Nam-Kwon (Department of Radiation Oncology, Korea University College of Medicine) ;
  • Park, Young-Je (Department of Radiation Oncology, Korea University College of Medicine) ;
  • Yang, Dae-Sik (Department of Radiation Oncology, Korea University College of Medicine) ;
  • Yoon, Won-Sup (Department of Radiation Oncology, Korea University College of Medicine) ;
  • Lee, Suk (Department of Radiation Oncology, Korea University College of Medicine) ;
  • Kim, Chul-Yong (Department of Radiation Oncology, Korea University College of Medicine)
  • 투고 : 2010.06.04
  • 심사 : 2010.09.17
  • 발행 : 2010.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 방사선치료 단독요법 또는 동시항암화학방사선치료(concurrent chemoradiation therapy, CCRT)를 시행한 코인두암 환자들의 장기 추적결과를 바탕으로 생존율 재발양상 부작용 및 예후인자를 분석하였다. 대상 및 방법: 1981년 12월부터 2006년 12월까지 코인두암으로 진단받고 고려대학교의료원 방사선종양학과에서 방사선치료를 시행한 190명의 환자를 대상으로 분석하였다. 연령은 8세부터 78세(중앙값 49세) 이었으며, 성별은 남자가 141명, 여자가 49명이었다. 조직학적 분류는 각질화암이 10명 비각질화암이 166명, 기저양평편상피암이 1명이었다. American Joint Committee on Cancer 병기 I이 7명(3.6%), IIA 8명 (4.2%), IIB 33명(17.4%), III 82명(43.2%), IVA 31명(16.3%), IVB 29명 (15.3%)이었으며, 방사선치료 단독요법으로 치료한 환자는 103명이었고, CCRT를 시행한 환자는 87명이었다. 원발병소에 조사된 방사선량은 일일 선량 1.8~2.0 Gy, 총선량 66.6~87 Gy, 중앙값 72 Gi 였다. 생존율, 예후인자 및 부작용에 대하여 후향적으로 분석하였고 급, 만성 부작용 평가는 Radiation Therapy Oncology Group 분류법을 이용하였다. 결과: 190명 중 184명(96.8%)이 계획된 치료를 마쳤으며 방사선치료 기간은 19~88일(중앙값 63일)이었다. 전체 환자의 추적관찰기간은 2~2787개월로 평균 73개월 중앙값 52개월 이었다. 93명(48.9%)의 환자에서 재발이 발생하였는데 국소재발이 44명(23.2%), 림프절재발 13명(6.8%), 원격전이가 49명(25.8%)이었고 원격전이 부위는 뼈, 폐, 간 전이가 각각 23, 18, 12명이었다. 5년 및 10년 전체 생존율(overall survival rate, OS)은 각각 55.6%, 44.5%이었고, 중앙값 52개월이었다. 무병생존율 (disease-free survival rate, DFS)은 5년, 10년이 각각 54.8%, 51.3%이었고, 질병특이생존율(disease-specific survival rate, DSS)은 5년, 10년이 각각 65.3%, 57.4%이었다. 단변량분석에서 CCRT를 받은 환자, 젊은 연령, 여성이 OS, DFS 및 DSS가 유의하게 높았고, CCRT를 시행한 환자와 기간이 짧았던 환자에서 유의하게 원격전이가 적었다. 다변량분석에서는 CCRT를 받은 환자, 여성에서 OS, DFS 및 DSS가 통계적으로 유의하게 높았고, 국소재발에는 성별, 원격전이에는 CCRT시행여부가 영향을 미친 요인으로 나타났다. 방사선치료 도중 발생한 부작용으로 3등급 이상의 점막염 혈액학적 부작용은 각각 42명(22.1%), 18명(9.5%)이었고, 치료기간이 연장된 환자가 59명이었다. 항암화학치료를 병용한 환자에서 통계적으로 의미 있게 부작용 발생빈도가 높았으나 치료기간의 연장에는 통계적으로 유의한 차이를 보이지 않았다. 추적관찰 기간 동안 3등급 이상의 청력장애, 턱관절장애가 각각 9, 6예가 있었다. 결론: 본 연구의 결과, CCRT를 시행한 환자, 여성, T-병기, N-병기 및 연령이 낮은 환자에서 생존율의 향상이 있음을 확인하였다. CCRT를 했을 때 생존율 향상과 원격전이율 감소를 보여 항암화학치료의 역할을 확인할 수 있었으나 항암화학치료의 동시병용이 반드시 국소 및 영역제어율의 향상을 가져오는 것은 아니었다. 따라서 CCRT의 부작용을 감안할 때 세기조절방사선치료(intensity modulated radiation therapy)와 같은 치료에서 각 치료 방법의 역할과 기여도에 대한 비교 연구가 향후 시행되어야 할 것이다.차이를 보이지 않았다. 추적관찰 기간 동안 3등급 이상의 청력장애, 턱관절장애가 각각 9, 6예가 있었다. 결론: 본 연구의 결과, CCRT를 시행한 환자, 여성, T-병기, N-병기 및 연령이 낮은 환자에서 생존율의 향상이 있음을 확인하였다. CCRT를 했을 때 생존율 향상과 원격전이율 감소를 보여 항암화학치료의 역할을 확인할 수 있었으나 항암화학치료의 동시병용이 반드시 국소 및 영역제어율의 향상을 가져오는 것은 아니었다. 따라서 CCRT의 부작용을 감안할 때 세기조절방사선치료(intensity modulated radiation therapy)와 같은 치료에서 각 치료 방법의 역할과 기여도에 대한 비교 연구가 향후 시행되어야 할 것이다

Purpose: To analyze the treatment outcomes, complications, prognostic factors after a long-term follow-up of patients with nasopharyngeal carcinoma treated with radiation therapy (RT) alone or concurrent chemoradiation therapy (CCRT). Materials and Methods: Between December 1981 and December 2006, 190 eligible patients with non-metastatic nasopharyngeal carcinoma were treated at our department with a curative intent. Of these patients, 103 were treated with RT alone and 87 patients received CCRT. The median age was 49 years (range, 8~78 years). The distributions of clinical stage according to the AJCC 6th edition included I: 7 (3.6%), IIA: 8 (4.2%), IIB: 33 (17.4%), III: 82 (43.2%), IVA: 31 (16.3%), IVB: 29 (15.3%). The accumulated radiation doses to the primary tumor ranged from 66.6~87.0 Gy (median, 72 Gy). Treatment outcomes and prognostic factors were retrospectively analyzed. Acute and late toxicities were assessed using the RTOG criteria. Results: A total of 96.8% (184/190) of patients completed the planned treatment. With a mean follow-up of 73 months (range, 2~278 months; median, 52 months), 93 (48.9%) patients had relapses that were local 44 (23.2%), nodal 13 (6.8%), or distant 49 (25.8%). The 5- and 10-year overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) rates were 55.6% and 44.5%, 54.8% and 51.3%, in addition to 65.3% and 57.4%, respectively. Multivariate analyses revealed that CCRT, age, gender, and stage were significant prognostic factors for OS. The CCRT and gender were independent prognostic factors for both DFS and DSS. There was no grade 4 or 5 acute toxicity, but grade 3 mucositis and hematologic toxicity were present in 42 patients (22.1%) and 18 patients (9.5%), respectively. During follow-up, grade 3 hearing loss in 9 patients and trismus in 6 patients were reported. Conclusion: The results of our study were in accordance with findings of previous studies and we confirmed that CCRT, low stage, female gender, and young age were related to improvement in OS. However, there are limitations in the locoregional control that can be achieved by CCRT with 20 conventional radiation therapy. This observation has led to further studies on clarifying the efficacy of concurrent chemotherapy by intensity modulated radiation therapy.

키워드

참고문헌

  1. Lee AW, Perez CA, Law SCK, et al. Nasopharynx. In: Perez CA, Brady LW, eds. Principles and practice of radiation oncology. 5th ed, Philadelphia: Lippincott Co., 2009:820-854
  2. Ministry for Health, Welfare and Family Affairs. Annual report of cancer incidence (2005) and surival (1993-2005) in Korea. Seoul: Ministry for Health, Welfare and Family Affairs, 2008:36-37
  3. Lee AW, Foo W, Law SC. et al. Nasopharyngeal carcinoma: presenting symptoms and duration before diagnosis. Hong Kong Med J 1997;3:355-361
  4. Ng WT, Lee AW, Kan WK, et al. N-staging by magnetic resonance imaging for patients with nasopharyngeal carcinoma: pattern of nodal involvement by radiological levels. Radiother Oncol 2007;82:70-75 https://doi.org/10.1016/j.radonc.2006.11.010
  5. Tang L, Mao Y, Liu L. et al. The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging. Cancer 2009;115:680-688 https://doi.org/10.1002/cncr.24049
  6. Lin JC, Jan JS , Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631-637 https://doi.org/10.1200/JCO.2003.06.158
  7. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-6738 https://doi.org/10.1200/JCO.2005.16.790
  8. Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005;23:6966-6975 https://doi.org/10.1200/JCO.2004.00.7542
  9. Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 2008;71:1356-1364 https://doi.org/10.1016/j.ijrobp.2007.12.028
  10. AI-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317
  11. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536-539 https://doi.org/10.1093/jnci/dji084
  12. AI-Saraf M, LeBlanc M, Giri PG, et al. Superiority of five year survival with chemo-radiotherapy (CT-RT) vs radiotherapy in patients (Pts) with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III Study: Final Report (abstract #905). Proc Am Soc Clin Oncol 2001;20:227a
  13. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 2002;25:219-223 https://doi.org/10.1097/00000421-200206000-00002
  14. Zhang L, Zhao C, Ghimire BR, Guo Y, Guan ZZ. The role of concurrent chemoradiation in the treatment of locally advanced nasopharyngeal carcinoma among endemic area: a meta-analysis of the phase III randomized trials. J Clin Oncol 2008;26(15 Suppl):6032 https://doi.org/10.1200/jco.2008.26.15_suppl.6032
  15. Kwong DL, Sham JS, Leung LH, et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal cacinoma. Int J Radiat Oncol Biol Phys 2006;64:374-381 https://doi.org/10.1016/j.ijrobp.2005.07.968
  16. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (lMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006;64:57-62 https://doi.org/10.1016/j.ijrobp.2005.03.057
  17. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53:12-22 https://doi.org/10.1016/S0360-3016(02)02724-4
  18. Waldron J, Tin MM, Keller A, et al. Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma. Radiother Oncol 2003;68:153-161 https://doi.org/10.1016/S0167-8140(02)00370-5
  19. Leibel SA, Kutcher GJ, Harrison LB, et al. Improved dose distributions for 3D conformal boost treatments in carcinoma of the nasopharynx. Int J Radiat Oncol Biol Phys 1991;20:823-833 https://doi.org/10.1016/0360-3016(91)90030-8
  20. Wadsley JC, Bentzen SM. Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;60:1405-1409 https://doi.org/10.1016/j.ijrobp.2004.05.049
  21. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-3576 https://doi.org/10.1200/JCO.2005.02.147
  22. Chan AT, Ma B, Hui EP, et al. Phase II study of gefitinib in metastatic or locoregionally recurrent nasopharyngeal carcinoma (NPC). J Clin Oncol 2006;24(18 Suppl):15509
  23. Chen E, Winquist E, Agulnik M, et al. A phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). Eur J Cancer Suppl 2005;3:297
  24. Lin S, Lu JJ , Han L, Chen Q, Pan J. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer 2010;10:39 https://doi.org/10.1186/1471-2407-10-39
  25. Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol 2003;4:13-21 https://doi.org/10.1016/S1470-2045(03)00956-2
  26. Bar-Sela G, Ben Arush MW, Sabo E, Kuten A, Minkov I, Ben-Izhak O. Pediatric nasopharyngeal carcinoma: better prognosis and increased c-Kit expression as compared to adults. Pediatr Blood Cancer 2005:45:291-297 https://doi.org/10.1002/pbc.20264
  27. Chen CY, Han F, Zhao C, et al. Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone. Br J Radiol 2009;82:452-458 https://doi.org/10.1259/bjr/72813246
  28. Teo P, Yu P, Lee WY, et al. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys 1996;36:291-304
  29. Farias TP, Dias FL, Lima RA, et al. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2003;129:794-799 https://doi.org/10.1001/archotol.129.7.794
  30. Yeh SA, Tang Y, Lui CC, Huang YJ, Huang EY. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 2005;62:672-679 https://doi.org/10.1016/j.ijrobp.2004.11.002
  31. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704 https://doi.org/10.1016/S0360-3016(01)01512-7
  32. Lee SH, Kim TH, Chie EK, et al. Evaluation of xerostomia following intensity modulated radiotherapy (lMRT) for head and neck cancer patients. J Korean Soc Ther Radiol Oncol 2004;22:106-114
  33. Sumitsawan Y, Chaiyasate S, Chitapanarux I, et al. Late complications of radiotherapy for nasopharyngeal carcinoma. Auris Nasus Larynx 2009;36:205-209 https://doi.org/10.1016/j.anl.2008.04.006
  34. Chan SH, Ng WT, Kam KL, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys 2009;73:1335-1342 https://doi.org/10.1016/j.ijrobp.2008.07.034